Your session is about to expire
← Back to Search
Amlitelimab dose 1 for Atopic Dermatitis (AQUA Trial)
AQUA Trial Summary
This trial is testing a new treatment for people with moderate-to-severe atopic dermatitis who have not responded well to other therapies. The study will compare the effectiveness and safety of the new treatment,
AQUA Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowAQUA Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.AQUA Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the safety profile of the initial dosage of amlitelimab in individuals?
"Based on the fact that this trial is in Phase 3, indicating previous evidence of safety and efficacy, our team at Power rates the safety of Amlitelimab dose 1 as a 3."
Are individuals currently being enrolled in this medical study?
"Correct. The details on clinicaltrials.gov affirm that this research project is actively seeking participants. It was initially listed on February 29th, 2024, and last modified on March 15th, 2024. They aim to recruit 249 patients from nine different sites."
Can you confirm if there are multiple locations conducting this clinical trial in North America?
"Encino Research Center Site Number : 8401042 in Encino, Center for Dermatology Clinical Research Site Number : 8401018 in Fremont, and Investigational Site Number : 1240028 in Regina are among the 9 sites actively seeking eligible participants for this research study."
How many individuals in total are enrolled in this clinical study?
"Indeed, as per clinicaltrials.gov, this trial is actively seeking participants. Originally posted on February 29th, 2024, and last updated on March 15th, 2024, the study aims to enroll a total of 249 individuals distributed across nine locations."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger